AfricaRegulatory
African Pharmaceutical Regulatory Intelligence
PRAZEPAM
7 registrations across 3 African markets— 5 active
Markets with PRAZEPAM
Recent registrations
| Brand / Product | Market | Holder | Status | Expires |
|---|---|---|---|---|
| LYSANXIA Gouttes buvables / 15 mg/ml | 🇹🇳Tunisia | PFIZER S.A MAROC | expired | Jul 2005 |
| LYSANXIA Comprimé sécable / 10 mg | 🇹🇳Tunisia | PFIZER S.A MAROC | expired | Apr 2005 |
| LYSANXIA comprime / 10 mg | 🇸🇳Senegal | ALFASIGMA | active | — |
| LYSANXIA goutte orale / 15mg/ml | 🇸🇳Senegal | PFIZER | active | — |
| LYSANXIA COMPRIME SECABLE | 🇲🇦Morocco | — | active | — |
| LYSANXIA comprime / 10 mg | 🇸🇳Senegal | ALFASIGMA | active | — |
| LYSANXIA SOLUTION POUR GOUTTES BUVABLES | 🇲🇦Morocco | — | active | — |
PRAZEPAM in Africa — Regulatory Overview
PRAZEPAM is registered across 3 African markets with 7 total product registrations on file. Data is sourced directly from official national drug regulatory authorities including Senegal, Morocco, Tunisia. AfricaRegulatory refreshes this data daily from official government sources.
Of the 7 registrations, 5 (71%) are currently active. Regulatory affairs teams use AfricaRegulatory to track registration expiry dates, identify market incumbents, and monitor approval status across African markets without manual monitoring of each national regulator.